Hologic/ACLA: Julie Khani
The American Clinical Laboratory Association said this week that President Julie Khani will depart the organization. She will be joining Hologic, where she will serve as vice president of government affairs. Khani has served as president of ACLA since January 2017. She joined ACLA in July 2013 and has also served as its senior vice president and executive vice president. Prior to ACLA, Khani was vice president, public policy, for the National Association of Chain Drug Stores. The ACLA board of directors has begun a national search for Khani's replacement.
Akoya Biosciences: Myla Lai-Goldman
Akoya Biosciences has appointed Myla Lai-Goldman to its board of directors. From 1990 to 2008, Lai-Goldman held various roles at Laboratory Corporation of America and its predecessor company, Roche Biomedical Laboratories, including executive vice president, chief medical officer, and chief scientific officer. She is currently the chair of precision medicine company GeneCentric Therapeutics, which she cofounded and for which she previously served as CEO and president. She is also a venture partner with Hatteras Venture Partners and managing partner of Personalized Science, a diagnostic consulting company that she founded in 2008. She is board certified in anatomic and clinical pathology, and received her medical degree from Columbia University College of Physicians and Surgeons.
Caris Life Sciences: Milan Radovich
Caris Life Sciences said this week that Milan Radovich has joined the firm as chief precision medicine officer. In this role, Radovich will lead Caris' biomarker and drug intelligence teams, aiming to develop novel signatures and drug targets. Before joining Caris, Radovich was an associate professor at the Indiana University School of Medicine, vice president for oncology genomics at Indiana University Health, and co-director of the IU Health Precision Genomics Program. As a National Cancer Institute-funded investigator, his research focused on the use of genomics in translational oncology, particularly on the use of genomics in clinical studies, genomically informed drug combinations, circulating biomarkers for cancer detection, and creating novel bioinformatic pipelines for cancer genome analyses.
For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.